Brickell anti-sweating drug submitted for final pre-market review in Japan
BOULDER — Brickell Biotech Inc. (Nasdaq: BBI) said its research partner has applied to sell the company’s flagship drug candidate in Japan after settling a wide-ranging intellectual-property lawsuit earlier this year.
In its earnings report Wednesday, the Boulder dermatology company posted a quarterly loss of $1.38 per share and had $11.7 million in cash and equivalents on hand. It has yet to receive U.S. Food and Drug Administration approval to sell any of its drug candidates.
Brickell and Japanese collaborator Kraken Pharmaceutical Co. Ltd. said it had positive Phase III data in Japanese trials for sofpironium…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Boulder-based publishing technology company Sovrn Holdings Inc. has named Will Duckworth its chief technology officer.
-
A Boulder fiber infrastructure company and broadband internet provider said it has raised $80 million…
-
Knowledge Factor Inc., a software-as-a-service company that provides cognitive science-based assessment, training and data analytics…
-
Tilled Inc., a Boulder payment-facilitation technology company, recently completed a $12.5 million investment round, bringing…
